Fig. 1.
Event‐free survival according to combinations of European Association of Urology (EAU) risk group (low vs high; panels A, B) and prostate‐specific membrane antigen‐positron emission tomography (PSMA‐PET) status (negative/local recurrence vs regional/distant metastasis; panels C, D) in combination with radiotherapy use (panels B, D) or no radiotherapy use (panels A, B) over 36 months of follow‐up.